Mohammad Mozayen, MD
Hematology & Oncology · Independence, MONPI 1437340668
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 297 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 20.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,627 and has fallen 54.3% since, to $1,201 in 2025.
Across 297 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$1K
- Pfizer$512
- Merck$435
- Novartis$373
- AbbVie$330
- AstraZeneca$326
- plus $3K from 35 others
Across 35 payments — averaging $1782.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$25K
- Ipsen Bioscience Inc.$24K
- Exelixis Inc.$14K
What the payments were for
- Food & beverage$6,40299%
- Education$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 7 | $1,333 |
| Pfizer | 42 | $512 |
| Merck | 24 | $435 |
| Novartis | 20 | $373 |
| AbbVie | 13 | $330 |
| AstraZeneca | 18 | $326 |
| Gilead(2 entities) | 15 | $302 |
| Johnson & Johnson | 12 | $249 |
| E.r. Squibb & Sons, L.L.C. | 18 | $242 |
| GSK | 11 | $211 |
| Genentech USA, Inc. | 11 | $201 |
| Bristol Myers Squibb | 11 | $192 |
| Eisai Inc. | 11 | $185 |
| Array Biopharma Inc | 12 | $181 |
| Regeneron Healthcare Solutions, Inc. | 8 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $131 |
| Daiichi Sankyo Inc. | 6 | $111 |
| Seagen Inc. | 5 | $87 |
| AVEO Pharmaceuticals, Inc. | 3 | $81 |
| Ipsen Biopharmaceuticals, Inc | 4 | $74 |
| Amgen | 4 | $72 |
| Karyopharm Therapeutics Inc. | 3 | $64 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $60 |
| Puma Biotechnology, Inc. | 3 | $53 |
| Incyte Corporation | 3 | $52 |
| Boehringer Ingelheim | 2 | $51 |
| Novocure Inc. | 3 | $45 |
| Pharmaessentia USA Corporation | 2 | $43 |
| Astellas Pharma US Inc | 2 | $41 |
| Sanofi | 2 | $40 |
| Lilly USA, LLC | 2 | $37 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $19 |
| Springworks Therapeutics, Inc. | 1 | $18 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Rigel Pharmaceuticals, Inc. | 1 | $16 |
| Genmab U.S., Inc. | 1 | $15 |
| Stemline Therapeutics Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cabometyx$1,216
How this compares
$6,457 in reported general payments places this provider in the 70th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 12 | $140,434 |
| EliquisApixaban | 44 | $34,514 |
| XareltoRivaroxaban | 47 | $29,261 |
| Exemestane | 12 | $4,992 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 69 | $2,001 |
| Anastrozole | 144 | $1,859 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 73 | $1,640 |
| Morphine Sulfate ErMorphine Sulfate | 58 | $1,473 |
| Fentanyl | 14 | $1,263 |
| Oxycodone Hcl | 67 | $1,171 |
| Ondansetron Hcl | 81 | $967 |
| Letrozole | 38 | $760 |
| Dexamethasone | 61 | $747 |
| Acyclovir | 21 | $402 |
| Hydroxyurea | 35 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $326 | $140,43412 claims |
| PfizerEliquis | $512 | $34,51444 claims |
| Johnson & JohnsonXarelto | $249 | $29,26147 claims |
| Lilly USA, LLCOlanzapine | $37 | $21221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Independence
- Aruna RokkamIndependence$9K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.